米安色林对首发抑郁症的临床疗效

To observe the efficacy of Mianserin in treatment of patients with first-episode depression

目的探讨米安色林治疗首发抑郁症的效果及安全性。方法将符合《国际疾病分类(第10版)》(ICD-10)的128例首发抑郁症患者随机分为米安色林组和氟西汀组各64例,疗程8周。用汉密尔顿抑郁量表(HAMD-17)和汉密尔顿焦虑量表(HAMA)评定疗效,副反应量表(TESS)评定安全性。结果米安色林组有效率92.2%,氟西汀组有效率89.1%,两组差异无统计学意义(P>0.05)。第2周末,米安色林组HAMD-17及HAMA评分分别为(16.25±2.397)分和(10.92±2.110)分,低于氟西汀组的(17.17±2.758)分和(12.02±2.134)分,差异有统计学意义(P<0.05)。米安色林组TESS评分为(4.80±3.80)分,氟西汀组为(5.20±3.65)分,差异无统计学意义(P>0.05)。结论米安色林治疗首发抑郁症患者较氟西汀起效快,但疗效及不良反应发生率相当。

Objective To observe the efficacy and safety of Mianserin in treatment of patients with first-episode depression. Methods 128 patients with first-episode depression were randomly divided into Mianserin group （64 cases treated with Mianserin）and Fluoxetine group （64 cases treated with Fluoxetine）for 8 weeks.The efficacy was assessed with HAMD and HAMA,while the adverse reactions were assessed with TESS.Results The effective rate of mianserin group is 92.2%,the effective rate of fluoxetine group is 89.1%.There are no differences between the two groups （P〉0.05）.But the scores of HAMD and HAMA of Mianserin group were lower than those of Fluoxetine group （P〈0.05）.Conclusion Mianserin is faster response, less adverse reactions than fluoxetine.It can improve sleep and anxiety symptom in treatment of patients with first-episode depression.